利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.025 秒)

    Inhibitors of akt activity
    3.
    发明申请
    Inhibitors of akt activity 审中-公开
    akt活性抑制剂

    公开(公告)号：US20050182256A1

    公开(公告)日：2005-08-18

    申请号：US10509959

    申请日：2003-04-04

    申请人： Mark Duggan ,  Craig Lindsley ,  Zhijian Zhao

    发明人： Mark Duggan ,  Craig Lindsley ,  Zhijian Zhao

    IPC分类号： A61K31/497 ,  A61K45/00 ,  A61P35/00 ,  A61P43/00 ,  C07D241/18 ,  C07D401/14 ,  C07D43/02

    CPC分类号： C07D401/14 ,  C07D241/18

    摘要： The present invention is directed to compounds comprising a 2,3-diphenylpyrazine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.

    摘要翻译： 本发明涉及包含抑制Akt（丝氨酸/苏氨酸蛋白激酶）活性的2,3-二苯基吡嗪部分的化合物。 本发明还涉及含有本发明化合物的治疗组合物和治疗癌症的方法，包括施用本发明化合物。

    Carbonylamino-benzimidazole derivatives as androgen receptor modulators
    6.
    发明申请
    Carbonylamino-benzimidazole derivatives as androgen receptor modulators 失效

    公开(公告)号：US20060036098A1

    公开(公告)日：2006-02-16

    申请号：US10533259

    申请日：2003-10-28

    申请人： Yuntae Kim ,  Barbara Hanney ,  Mark Duggan ,  Keith Spencer

    发明人： Yuntae Kim ,  Barbara Hanney ,  Mark Duggan ,  Keith Spencer

    IPC分类号： C07D403/02 ,  A61K31/4184

    CPC分类号： C07D417/04 ,  C07D401/04 ,  C07D403/04 ,  C07D417/14

    摘要： Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, arthritic condition and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer s disease, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.